What were the results of the Propen-sity Score-Matched Post Hoc Analysis regarding the use of Recombinant Tissue-Type Plasminogen Activator plus Eptifibatide versus Recombinant Tissue-Type Plasminogen Activator alone in Acute Ischemic Stroke?
The Propen-sity Score-Matched Post Hoc Analysis regarding the use of Recombinant Tissue-Type Plasminogen Activator plus Eptifibatide versus Recombinant Tissue-Type Plasminogen Activator alone in Acute Ischemic Stroke found that the combined approach resulted in improved outcomes, with a 24.8% absolute improvement in functional independence at 90 days and a 27.3% absolute improvement in mortality at 90 days. These results were statistically significant. Additionally, there was a trend towards improved recanalization rates with the combined approach. However, this improvement did not reach statistical significance.  